The protocols differ in important ways, and understanding those differences is essential for anyone planning a research protocol
doi: 10.1016/j.immuni.2022.10.014 16 AppledornDMPatialSMcBrideAGodbehereSVan RooijenNParameswaranNet al
Epub 2023 Oct 8
Other Ingredients: Lactose Monohydrate, BulkingAgent [INS 460(i)], Binder (INS 462), Disintegrant (INS 468), Sodium Starch, Glycolate, Lubricant [INS 470(i)], Glidant (INS 551), Thickener (INS 464), Diethyl Phthalate, Plasticizer (INS 1518 & INS 1521)
Patients should receive counseling that reduced appetite represents an expected pharmacological effect rather than a concerning symptom
Glucose is the standard osmotic agent, although icodextrin and amino acids are also available options.42 Reducing glucose exposure in PD solutions is beneficial for various reasons, including the attempt to overcome some degree of insulin resistance in the diabetic patient.1 Biocompatibility of a PD solution is defined as its capacity to leave the anatomical and functional properties of the peritoneal membrane unmodified over time
